Featured Paper of the Month – May 2026
Summary
Buprenorphine is an FDA-approved medication for opioid addiction, but the brain regions underlying its therapeutic effects are unknown. We previously found that chronic buprenorphine treatment, used to model opioid maintenance therapy, decreases several relapse-related behaviors in rats. Here, we tested whether chronic buprenorphine reduces the time-dependent increase (“incubation”) in heroin seeking during abstinence. We also used the activity marker Fos to determine whether buprenorphine’s inhibition of incubation of heroin seeking is associated with decreased activation in cortical and striatal regions. We found that chronic buprenorphine reduced both the incubation of heroin seeking and the associated neuronal activation in several cortical and striatal areas. These results support thepredictive validity of the rat model of incubation of opioid craving and suggest that buprenorphine’s therapeutic effects are linked to reduced neuronal activity in specific subregions of the medial prefrontal cortex and striatum involved in drug craving and relapse.
Publication Information
In: Psychopharmacology (Berl), 2025, ISSN: 1432-2072.

